Biotech Downgrades Hit Ultragenyx on Trial Failure, Moderna on Valuation

Evercore ISI cut its rating on Ultragenyx Pharmaceutical after one of the company's clinical trials failed, a setback that undercuts the pipeline case investors had been relying on. Trial failures typically remove a near-term catalyst and push out the timeline for any product to reach the market. Separately, Rothschild Redburn downgraded Moderna, citing valuation concerns rather than any new negative clinical or regulatory news. That distinction matters: the Moderna call is about price relative to prospects, not a change in the underlying business. Both downgrades add to a rougher stretch for biotech stocks, though the drivers differ. Ultragenyx's setback is company-specific and tied to a failed study, while Moderna's downgrade reflects broader questions about how much investors should pay for the stock at current levels.